Document:

EX-10.21

 Exhibit 10.21 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is made by and amongst
ACUTUS MEDICAL, INC. (the “Company”), having its principal offices at
2210 Faraday Ave., Suite 100 Carlsbad, CA 92008, and Steve McQuillan (the “Executive”), effective as of September 6, 2016. 

WHEREAS, the Company desires to employ the Executive in the position of Senior Vice-President of
Clinical, Regulatory and Quality of the Company; and 
 WHEREAS, the Executive desires to be employed
by the Company as its Senior Vice-President of Clinical, Regulatory and Quality. 
 NOW
THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Executive hereby agree as follows: 

1.    Definitions. For purposes of this Agreement, the following terms shall have the meanings set forth
below: 
 (a)    “Annual Base Salary” shall mean the Executive’s rate of regular base
annual compensation prior to any reduction under (i) a salary reduction agreement pursuant to Section 401(k) or Section 125 of the Code or (ii) any plan or arrangement deferring any base salary. 

(b)    “Board” shall mean the Board of Directors of the Company. 

(c)    “Cause” any of the following: (i) the Executive’s failure to perform the
Executive’s assigned duties or responsibilities pursuant to this Agreement (other than a failure resulting from the Executive’s Disability) after notice thereof from the Company describing the Executive’s failure to perform such
duties or responsibilities; (ii) the Executive’s engaging in any act of dishonesty, fraud, misrepresentation, embezzlement or other acts that are or would reasonably be expected to be injurious in a material respect to the Company;
(iii) the Executive’s violation of any federal or state law or regulation applicable to the business of the Company or its affiliates; (iv) the Executive’s breach of any confidentiality agreement or invention assignment agreement
between the Executive and the Company (or any affiliate of the Company); (v) the Executive’s being convicted of, or entering a plea of nolo contendere to, any crime or committing any act of moral turpitude; (vi) the Executive’s
continuing gross negligence or gross misconduct after notice thereof from the Company describing the applicable conduct; or (vii) the Executive’s breach of any material term of any employment agreement between the Executive and the
Company. 
 (d)    “Change in Control” shall have the meaning ascribed to it in the
Company’s 2011 Equity Incentive Plan, as it may be amended from time to time. 
 (e)    “Change in
Control Period” shall mean the period commencing ninety (90) days prior to the effective date of a Change in Control and ending twelve (12) months following the effective date a Change in Control. 

(f)    “COBRA” shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended, as well as any state law of similar effect. 

 (g)    “Code” shall mean the Internal
Revenue Code of 1986, as amended, and, as applicable, Treasury Regulations promulgated thereunder. 

(h)    “Confidential Information Agreement” shall mean the
At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement that the Executive has entered or is required to enter into with the Company in connection with the Executive’s
employment with the Company. 
 (i)    “Date of Termination” shall mean the date of the
termination of the Executive’s employment. 
 (j)    “Disability” shall mean the
Executive’s disability within the meaning of Treasury Regulation Section 1.409A-3(i)(4)(i). 

(k)    “Good Reason” shall mean the Executive’s resignation within thirty
(30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without the Executive’s consent: (i) a material reduction of the Executive’s authority,
duties or responsibilities; (ii) a reduction of more than ten percent (10%) by the Company (or its successor) in the Executive’s base cash compensation as in effect immediately prior to such reduction, unless the Company also similarly
reduces the base cash compensation of all other similarly situated service providers of the Company; or (iii) a material change in the geographic location of the Executive’s primary work facility or location; provided, that a relocation of
less than fifty (50) miles from the Executive’s then-present location will not be considered a material change in geographic location. The Executive may not resign for Good Reason without first providing the Company with written notice of
the acts or omissions constituting the grounds for “Good Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a reasonable cure period of thirty (30) days following the date the
Company receives such notice during which such condition must not have been cured. 

(l)    “Qualifying Termination” shall mean the Company’s termination of the
Executive’s employment other than for Cause, death, or Disability or the Executive’s resignation for Good Reason. 

(m)    “Release” shall mean a general release of the Executive of any claims related to or
arising from Executive’s service with or separation from the Company (which may include an agreement not to disparage the Company, non-solicit provisions and other standard terms and conditions) in a form
reasonably satisfactory to the Company. The Release must be signed by the Executive and become irrevocable and effective in accordance with its terms not later than sixty (60) days following the Date of Termination. 

(n)    “Severance Commencement Date” shall mean the date on or following the Date of
Termination and on which the Release becomes effective and irrevocable in accordance with its terms; provided, however, that if the Date of Termination occurs within sixty (60) days prior to the end of a calendar year, the Severance
Commencement Date will be the later of (i) the date on which the Release becomes effective and irrevocable in accordance with its terms, or (i) the first day of the calendar year immediately following the Date of Termination. 

  
 2 

 2.    Term of this Agreement. The term of this Agreement,
as amended, shall commence upon the date of this Agreement set forth above and shall continue until terminated in accordance with Section 5 (the “Term”). 

3.    Duties; Scope of Employment; Compensation and Benefits. 

(a)    Position and Duties. The Company shall employ the Executive to the position of Senior Vice-President
of Clinical, Regulatory and Quality of the Company. During the Term, the Executive will devote substantially all of the Executive’s business efforts and time to the Company. The Executive agrees not to actively engage in any other employment,
occupation or consulting activity for any direct or indirect remuneration without the prior approval of the Board. 

(b)    Annual Base Salary. The Executive’s Annual Base Salary shall equal $300,000. The Annual Base
Salary amount shall be subject to review and may be adjusted based upon the Company’s normal performance review practices. The Annual Base Salary will be paid periodically in accordance with the Company’s normal payroll practices and be
subject to the usual, required withholdings. 
 (c)    Bonus. The Executive’s annual target bonus
opportunity shall be 30% of the Executive’s Annual Base Salary (the “Target Bonus”). The Target Bonus amount shall be subject to review and may be adjusted based upon the Company’s normal performance review
practices. The Executive’s actual annual bonus earned shall be determined based on the Executive’s performance and achievement of target objectives and such other terms to be determined by the Board in its sole discretion. Any such annual
bonus that is earned will be paid, less applicable withholdings, no later than the payroll period after the Board determines that such annual bonus has been earned, but in no event shall such earned annual bonus be paid after the later of
(i) the fifteenth (15th) day of the third (3rd) month following the close of the Company’s fiscal year in which the annual bonus is
earned or (ii) March 15 following the calendar year in which the annual bonus is earned. 

(d)    Employee Benefits. During the Term, the Executive and the Executive’s dependents, if applicable,
shall be eligible to participate in the employee benefit plans and programs currently and hereafter sponsored by the Company on the same terms and conditions generally applicable to similarly situated executives of the Company. The Company reserves
the right to cancel or change the employee benefit plans and programs it offers to its employees at any time. 

(e)    Equity Plans. The Executive shall be eligible to participate in any stock option, restricted stock,
stock appreciation rights, or any other equity compensation plan or program sponsored by the Company or its affiliates on the terms and conditions determined by the Board in its sole discretion. 

(f)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by the Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with the applicable policy of the Company, as in effect from time to time. 

  
 3 

 (g)    Paid Time Off. The Executive shall be entitled to
paid time off in accordance with the Company’s paid time off policy, as in effect from time to time. 

4.    At-Will Employment. The parties agree that the
Executive’s employment with the Company will be “at-will” employment and may be terminated at any time with or without cause or notice. The Executive understands and agrees that neither his job
performance nor promotions, commendations, bonuses, or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of his employment with the Company. However, as
described in this Agreement, the Executive may be entitled to severance benefits depending on the circumstances of the termination of the Executive’s employment with the Company. 

5.    Termination. The Term and the Executive’s employment shall terminate upon the occurrence of any
of the following events: 
 (a)    Qualifying Termination Outside of the Change in Control Period. 

(i)    The Company may remove the Executive at any time, with or without Cause, from the position in which the
Executive is employed hereunder, with or without notice. 
 (ii)    Upon a Qualifying Termination outside of the
Change in Control Period, the Executive shall be entitled to receive, subject to the effectiveness and irrevocability of the Release, the following severance benefits, subject to standard deductions and withholdings: 

(1)    The Executive shall receive cash severance equal to 50 % of the Annual Base Salary in effect
immediately prior to the Date of Termination (or if the Qualifying Termination is due to a resignation for Good Reason based on a material reduction in base cash compensation, then the Executive’s Annual Base Salary in effect immediately prior
to such reduction). Subject to any delay in payment required by Section 5(d), the Company will pay such cash severance, in substantially equal installments on the Company’s regular payroll schedule over the
six-month period immediately following the Date of Termination. However, no payments of such cash severance will be made prior to the Severance Commencement Date. On the first payroll pay day on or following
the Severance Commencement Date, the Company will pay the Executive in a lump sum the cash severance the Executive would otherwise have received on or prior to such date but for the delay in payment related to the effectiveness and irrevocability of
the Release, with the balance of the cash severance being paid as originally scheduled; and 
 (2)    If the
Executive timely elects continuation health care coverage pursuant to COBRA for himself and/or his eligible dependents, the Company will reimburse the Executive for the applicable COBRA premiums for such coverage for up to six months, or such
earlier time as the Executive ceases to be eligible for such continuation coverage; provided, however, that if the Company determines in its sole discretion that it cannot make the COBRA reimbursements without potentially violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), the Company will in lieu thereof provide to Executive a taxable monthly payment, payable on the last day of a given month, in an amount equal to the monthly COBRA
premium that the Executive would be 

  
 4 

 
required to pay to continue the Executive’s group health coverage in effect on the termination of employment date (which amount will be based on the premium for the first month of COBRA
continuation coverage), which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence on the month following the Executive’s termination of employment and will end on the earlier of
(x) the date upon which the Executive obtains other employment or (y) the date the Company has paid an amount equal to six monthly payments. For the avoidance of doubt, the taxable payments in lieu of COBRA reimbursements may be used for
any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholding. 

(b)    Qualifying Termination During the Change in Control Period. Upon a Qualifying Termination during the
Change in Control Period, then subject to the Executive’s timely provision of an effective and irrevocable Release, and effective as of the later of the Severance Commencement Date or the effective date of the Change in Control, the Executive
will be entitled to receive the following severance benefits, subject to standard deductions and withholdings: 

(i)    the Executive shall receive cash severance equal to 100% of the sum of the Annual Base Salary and the Target
Bonus, each as in effect immediately prior to the Date of Termination (or if the Qualifying Termination is due to a resignation for Good Reason based on a material reduction in base cash compensation, then the Executive’s Annual Base Salary or
Target Bonus in effect immediately prior to such reduction, as applicable). Subject to any delay in payment required by Section 5(d), such cash severance will be paid in a single lump sum on the first regular payroll pay day on or following the
Severance Commencement Date; 
 (ii)    the Executive shall receive a
lump-sum payment equal to (A) the Target Bonus that the Executive would have earned for the fiscal year in which the Executive’s Qualifying Termination occurs had the Executive remained employed with
the Company through the date the Executive was required to continue employment with the Company in order to be eligible to receive such bonus multiplied by (B) the fraction obtained by dividing (x) the number of days the Executive has
worked during such fiscal year by (y) the total number of days in such fiscal year, which will be paid at the same time as other similarly situated employees of the Company receive bonus payments for the fiscal year but in no event later than
March 15 of the year following the year of the Qualifying Termination, subject to any delay in payment required by Section 5(d); 

(iii)    if the Executive timely elects continuation health care coverage pursuant to COBRA for himself and/or his
eligible dependents, the Company will reimburse the Executive for the applicable COBRA premiums for such coverage for up to twelve months, or such earlier time as the Executive ceases to be eligible for such continuation coverage; provided, however,
that if the Company determines in its sole discretion that it cannot make the COBRA reimbursements without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will in
lieu thereof provide to Executive a taxable monthly payment, payable on the last day of a given month, in an amount equal to the monthly COBRA premium that the Executive would be required to pay to continue the Executive’s group health coverage
in effect on the termination of employment date (which amount will be based on the premium for the first month of COBRA continuation coverage), 

  
 5 

 
which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence on the month following the Executive’s termination of employment and will
end on the earlier of (x) the date upon which the Executive obtains other employment or (y) the date the Company has paid an amount equal to twelve monthly payments. For the avoidance of doubt, the taxable payments in lieu of COBRA
reimbursements may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholding; and 

(iv)    the Executive’s equity awards will accelerate vesting in full. For purposes of determining the number
of shares that will vest pursuant to the foregoing provision with respect to any performance-based vesting equity award, the applicable performance criteria shall be deemed to have been attained at a 100% level. 

(c)    Termination for Cause or Due to Death or Disability; Voluntary Resignation Without Good Reason. In the
event that the Executive voluntarily terminates his employment for any reason other than Good Reason or in the event that Company terminates the Executive’s employment for Cause or due to the Executive’s death or Disability, no further
payments shall be due under this Agreement, except that the Executive shall be entitled to any amounts earned, accrued or owing but not yet paid under Section 3 above, and any benefits accrued or earned under the Company’s benefit plans
and programs or to which the Executive is otherwise entitled under applicable law. 
 (d)    Compliance with
Section 409A of the Code. 
 (i)    Notwithstanding anything to the contrary in this Agreement, no
severance pay or benefits to be paid or provided to the Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Code
Section 409A, and the final regulations and any guidance promulgated thereunder (“Section 409A”) (together, the “Deferred Payments”) will be paid or
otherwise provided until the Executive has a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to the Executive, if any, pursuant to this Agreement that otherwise would be exempt from
Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until the Executive has a “separation from service” within the meaning of Section 409A. 

(ii)    Any severance payments or benefits under this Agreement that would be considered Deferred Payments will be
paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following the Executive’s separation from service, or, if later, such time as required by
Section 5(d)(iv). Except as required by Section 5(d)(iv), any installment payments that would have been made to the Executive during the sixty (60) day period immediately following the Executive’s separation from service but for
the preceding sentence will be paid to the Executive on the sixtieth (60th) day following the Executive’s separation from service and the remaining payments shall be made as provided in this
Agreement. 
 (iii)    It is intended that each installment of the payments provided for in this Section 5
is a separate “payment” for purposes of Treasury Regulations Section 1.409A- 2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the amounts set forth in 

  
 6 

 
this Section 5 satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation
1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), and any amounts paid under this Agreement that qualify under either of such exemptions will not constitute Deferred Payments for
purposes of clause (i) above. 
 (iv)    Any provision of this Agreement to the contrary notwithstanding,
if, at the time of the Executive’s Date of Termination, the Executive is a “specified employee,” within the meaning of Section 409A of the Code, then to the extent any payment or benefit that the Executive becomes entitled to
under this Agreement on account of his separation from service would be considered nonqualified deferred compensation under Section 409A of the Code, such payment or benefit shall be paid or provided at the date which is the earlier of
(i) six (6) months and one day after the Date of Termination and (ii) the date of the Executive’s death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant
to this Section 5(d) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or provided to the Executive in a lump-sum, and any
remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. 

(v)    Any reimbursements provided under this Agreement that constitute deferred compensation within the meaning
of Section 409A of the Code shall be made or provided in accordance with the requirements of Section 409A of the Code, including, without limitation, that (i) in no event shall any fees, expenses or other amounts eligible to be
reimbursed by the Company under this Agreement be paid later than the last day of the calendar year next following the calendar year in which the applicable fees, expenses or other amounts were incurred; (ii) the amount of expenses eligible for
reimbursement in any given calendar year shall not affect the expenses that the Company is obligated to reimburse in any other calendar year, provided that the foregoing clause (ii) shall not be violated with regard to expenses reimbursed under
any arrangement covered by Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect; (iii) the Executive’s right to have the Company pay or provide such reimbursements
may not be liquidated or exchanged for any other benefit; and (iv) in no event shall the Company’s obligations to make such reimbursements apply later than the Executive’s remaining lifetime. 

(vi)    The foregoing provisions are intended to comply with the requirements of Section 409A so that none of
the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and the Executive agree to work together in
good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under
Section 409A. 
 (e)    Non-Duplication of Payment or Benefits.
If (i) a Qualifying Termination occurs prior to a Change in Control that qualifies the Executive for severance payments and benefits under Section 5(a) and (ii) a Change in Control occurs within the 3-month period following the Qualifying Termination that qualifies Executive for severance payments and benefits under Section 5(b), then (A) the Executive will cease receiving any further payments or

  
 7 

 
benefits under Section 5(a) and (B) the Executive will receive the payments and benefits under Section 5(b) instead but each of the payments and benefits otherwise payable under
Section 5(b) will be offset by the corresponding payments or benefits the Executive already received under Section 5(a). 

6.    Confidential Information. The Executive agrees to enter into the Company’s standard At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (the “Confidential Information Agreement”) upon commencing employment hereunder. 

7.    Limitation on Payments; Section 280G. 

(a)    In the event the severance and other benefits provided for in this Agreement or otherwise payable to the
Executive (i) are “parachute payments” within the meaning of Section 280G of the Internal Revenue Code (the “Code”) and (ii) but for this Section 7, would be subject to the excise tax imposed by
Section 4999 of the Code, then the Executive’s severance benefits will be either. 
 (i)    delivered
in full, or 
 (ii)    delivered as to such lesser extent which would result in no portion of such severance
benefits being subject to the excise tax under Section 4999 of the code, 
 whichever of (a) or (b), taking into account the applicable federal,
state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by the Executive on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some
portion of such benefits may be taxable under Section 4999 of the Code. If a reduction in the severance and other benefits constituting “parachute payments” is necessary so that no portion of such severance benefits is subject to
excise tax under Section 4999 of the Code, (x) the Executive will have no rights to any additional payments and/or benefits that are being reduced, and (y) the reduction shall occur in the following order: (1) reduction of the
cash payments, if any, which shall occur in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first cash payment to be reduced;
(2) cancellation of accelerated vesting of equity awards other than stock options, if any; (3) cancellation of accelerated vesting of stock options, if any; and (4) reduction of other benefits, if any, paid or provided to the
Executive, which shall occur in reverse chronological order such that the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced. In the event that acceleration of
vesting of equity awards or stock options is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of the Executive’s equity awards or stock options. If two or more equity awards or stock
options are granted on the same date, each award or stock option will be reduced on a pro-rata basis. Notwithstanding, any excise tax imposed will be solely the responsibility of the Executive. Notwithstanding
the foregoing, to the extent the Company submits any payment or benefit otherwise payable to the Executive under this Agreement or otherwise to the Company’s stockholders for approval in accordance with Treasury Regulation Section 1.280G-1 Q&A 7, and such payments and benefits will be treated in accordance with the results of such vote, the foregoing provisions shall not apply following such submission and such

  
 8 

 
payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver of, such payments or benefits required by such vote will be applied
without any application of discretion by the Executive and in the order prescribed by this Section 7(a). In no event shall the Executive have any discretion with respect to the ordering of the Executive’s payment reductions. 

(b)    Unless the Company and the Executive otherwise agree in writing, any determination required under this
Section 7 will be made in writing by a nationally recognized firm of independent public accountants selected by the Company, the Company’s legal counsel or such other person or entity to which the parties mutually agree (the
“Firm”) whose determination will be conclusive and binding upon the Executive and the Company for all purposes. For purposes of making the calculations required by this Section 7, the Firm may make reasonable assumptions
and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the Executive will furnish to the Firm such information and
documents as the Firm may reasonably request in order to make a determination under this Section 7. The Company will bear all costs the Firm may reasonably incur in connection with any calculations contemplated by this Section 7. 

8.    Miscellaneous. 

(a)    Legal Costs. The Company shall reimburse the Executive for reasonable legal fees and expenses incurred
if the Executive prevails on any issue which is the subject of such of a lawsuit or arbitration brought by the Executive or the Company as a result of any dispute with any party (including, but not limited to, the Company and/or any affiliate of the
Company) regarding the provisions of this Agreement. Otherwise, the Executive and the Company shall be responsible for its own legal fees and expenses in connection with such action. The Company will reimburse the Executive for reasonable legal fees
and expenses directly relating to the negotiation of this Agreement, in accordance with the applicable policy of the Company. 

(b)    Arbitration. Executive agrees that any and all controversies, claims, or disputes with anyone
(including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s service to the Company, will be subject to
arbitration in accordance with the provisions of the Confidential Information Agreement. 
 (c)    No
Mitigation. The Company agrees that, if the Executive’s employment is terminated during the Term, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable to the Executive by the Company
pursuant to this Agreement. Further, the amount of any payment or benefit provided for in Section 5 of this Agreement shall not be reduced by any compensation earned by the Executive as the result of employment by another employer, by
retirement benefits, or offset against any amount claimed to be owed by the Executive to the Company or any of their respective subsidiaries. However, the severance benefits provided under this Agreement are intended to satisfy, to the greatest
extent possible, any and all statutory obligations that may arise out of the Executive’s termination of employment including, without limitation, the Worker Adjustment and Retraining Notification Act. 

  
 9 

 (d)    Successors. In addition to any obligations imposed
by law upon any successor to the Company, the Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to expressly
assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. 

(e)    Binding Agreement. This Agreement shall inure to the benefit of and be enforceable by the
Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive shall die while any amount would still be payable to the Executive hereunder (other than amounts
which, by their terms, terminate upon the death of the Executive) if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal
representatives or administrators of the Executive’s estate. 
 (f)    Notices. For the purpose of
this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States certified mail, return receipt requested, postage prepaid,
addressed to the respective addresses set forth below, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:

 To the Company: 
 2210
Faraday Ave. 
 Suite 100 

Carlsbad, CA 92008 
 To the
Executive: 
 Steve McQuillan 

At the address most recently on file with the Company 

(g)    Amendments. No provision of this Agreement may be modified, waived or discharged unless such waiver,
modification or discharge is agreed to in writing and signed by the Executive and such officer as may be specifically designated by the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. 

(h)    Entire Agreement. Except as otherwise provided, this Agreement (including any documents referred to
herein) contains the entire agreement between the parties concerning the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, express or implied, between the
parties with respect thereto. 

  
 10 

 (i)    Applicable Law. The validity, interpretation,
construction and performance of this Agreement shall be governed by the laws of the State of California without regard to the principles of conflict of laws thereof. 

(j)    Captions. The captions of this Agreement are not part of the provisions hereof and shall have no force
or effect. 
 (k)    Withholding. Any payments provided for hereunder shall be paid net of any applicable
withholding required under federal, state or local law and any additional withholding to which the Executive has agreed. 

(l)    Survivorship. The rights and obligations of the Company and the Executive under this Agreement shall
survive the expiration of the Term. 
 (m)    Mutual Intent. All parties participated in the drafting of
the Agreement, and the language used in this Agreement is the language chosen by the Executive and the Company to express their mutual intent. The parties agree that in the event that any language, section, clause, phrase or word used in the
Agreement is determined to be ambiguous, no presumption shall arise against or in favor of either party and that no rule of strict construction shall be applied against either party with respect to such ambiguity. 

(n)    Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 

(o)    Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed to
be an original but all of which together will constitute one and the same instrument. 
 IN WITNESS
WHEREOF, the parties hereto have executed this Agreement as of the date first written above. 

  
 11 

 
			
	ACUTUS MEDICAL, INC.
		
	By:	 	/s/ Vince Burgess
	Name:	 	Vince Burgess
	Title:	 	Board Member

  

	
	EXECUTIVE
	
	/s/ Steve McQuillan

 
			
	Steve McQuillan	 	9/29/2016EX-10.22

 Exhibit 10.22 

ACUTUS MEDICAL, INC. 

CONSULTING AGREEMENT 
 This
Consulting Agreement (this “Agreement”) is made and entered into as of 1/4/2019 (the “Effective Date”) by and between Acutus Medical, Inc., a Delaware corporation with its principal place of
business at Faraday Avenue, Suite 100, San Diego, CA 92008 (the “Company”), and Elia Health Sciences, Inc., with a principal place of business/residence at [****] (“Consultant’) (each herein referred
to individually as a “Party,” or collectively as the “Parties”). 
 The Company desires to retain
Consultant as an independent contractor to perform consulting services for the Company, and Consultant is willing to perform such services, on the terms described below. In consideration of the mutual promises contained herein, the Parties agree as
follows: 
 1. Services and Compensation 

Consultant shall perform the services described in Exhibit A (the “Services”) for the Company (or its designee,)
and the Company agrees to pay Consultant the compensation described in Exhibit A for Consultant’s performance of the Services. 

2. Applicability to Past Activities 

Company and Consultant acknowledge that Consultant may have performed work, activities, services or made efforts on behalf of or for the
benefit of Company, or related to the current or prospective business of Company in anticipation of Consultant’s involvement with Company, that would have been “Services” if performed during the term of this Agreement, for a period of
time prior to the date of this Agreement (the “Prior Consulting Period” ). Accordingly, Consultant agrees that if and to the extent that, during the Prior Consulting Period: (i) Consultant received access to any
information from or on behalf of Company that would have been “Confidential Information” (as defined below) if Consultant received access to such information during the term of this Agreement; or (ii) Consultant conceived, created,
authored, invented, developed or reduced to practice any item (including any intellectual property rights with respect thereto) on behalf of or for the benefit of Company that would have been an “Invention” (as defined below) if conceived,
created, authored, invented, developed or reduced to practice during the term of this Agreement; then any such information shall be deemed “Confidential Information” hereunder and any such item shall be deemed an “ Invention”
hereunder, and this Agreement shall apply to such activities, information or item as if disclosed, conceived, created, authored, invented, developed or reduced to practice during the term of this Agreement. 

3. Confidentiality 
 A.
Definition of Confidential Information. “Confidential Information” means any non-public information that relates to the actual or anticipated business and/or
products, research or development of the Company, its affiliates or subsidiaries or to the Company’s, its affiliates’ or subsidiaries’ technical data, trade secrets, or know-how, including, but
not limited to, research, product plans, or other information regarding the Company’s, its affiliates’ or subsidiaries’ products or services and markets therefor, customer lists and customers (including, but not limited to, customers
of the Company whom Consultant became acquainted during the term of this Agreement), software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and
other business information disclosed by the Company, its affiliates or subsidiaries, either directly or indirectly, in writing, orally or by drawings or inspection of premises, parts, equipment or other property of Company, its affiliates or
subsidiaries. 

 
Notwithstanding the foregoing, Confidential Information shall not include any such information which Consultant can establish (i) was publicly known or made generally available prior to the
time of disclosure to Consultant; (ii) becomes publicly known or made generally available after disclosure to Consultant through no wrongful action or inaction of Consultant; (iii) is in the rightful possession of Consultant, without
confidentiality obligations, at the time of disclosure as shown by Consultant’s then- contemporaneous written records; or (iv) is subsequently developed by Consultant without reliance upon the
Company’s Confidential Information, as supported by written records or other competent evidence kept in the ordinary course of business. 

B. Nonuse and Nondisclosure. During and after the term of this Agreement, Consultant will hold in the strictest
confidence, and take all reasonable precautions to prevent any unauthorized use or disclosure of Confidential Information, and Consultant will not (i) use the Confidential Information for any purpose whatsoever other than as necessary for the
performance of the Services on behalf of the Company, or (ii) disclose the Confidential Information to any third party without the prior written consent of an authorized representative of Company. Consultant may disclose Confidential
Information to the extent compelled by applicable law; provided however, prior to such disclosure, Consultant shall provide prior written notice to Company and seek a protective order or such similar confidential protection as may be
available under applicable law. Consultant agrees that no ownership of Confidential Information is conveyed to the Consultant. Without limiting the foregoing, Consultant shall not use or disclose any Company property, intellectual property rights,
trade secrets or other proprietary know-how of the Company to invent, author, make, develop, design, or otherwise enable others to invent, author, make, develop, or design identical or substantially similar
designs as those developed under this Agreement for any third party. Consultant may disclose the existence of this Agreement and the fact that Consultant is providing services to the Company; provided, however, that Consultant shall
not disclose the material or commercial terms of this Agreement (other than with Consultant’s accountants, tax preparers or attorneys) without the consent of the Company. Consultant agrees that Consultant’s obligations under this
Section 3.B shall continue after the termination of this Agreement. 
 C. Other Client Confidential Information.
Consultant agrees that Consultant will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any former or concurrent employer of Consultant or other person or entity with which Consultant has an
obligation to keep in confidence. Consultant also agrees that Consultant will not bring onto the Company’s premises or transfer onto the Company’s technology systems any unpublished document, proprietary information, or trade secrets
belonging to any third party unless disclosure to, and use by, the Company has been consented to in writing by such third party. 
 D.
Third Party Confidential Information. Consultant recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company’s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees, to the extent that the Company’s confidentiality obligations based on the circumstances of disclosure or the nature of
the subject matter itself, that at all times during the term of this Agreement and thereafter, Consultant owes the Company and such third parties a duty to hold all such confidential or proprietary information in the strictest confidence and not to
use it or to disclose it to any person, firm, corporation, or other third party except as necessary in carrying out the Services for the Company consistent with the Company’s agreement with such third party. 

  
 -2- 

 4. Ownership 

A. Assignment of Inventions. Consultant agrees that all right, title, mid interest in and to any copyrightable material, notes,
records, drawings, designs, inventions, improvements, developments, discoveries and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by Consultant, solely or in collaboration with others, during the term of
this Agreement and arising directly and solely out of, or in connection with, performing the Services under this Agreement and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing
(collectively, “Inventions” ), are the sole properly of the Company. Consultant also agrees to promptly make full written disclosure to the Company of any Inventions and to deliver and assign (or cause to be assigned) and
hereby irrevocably assigns folly to the Company all right, title and interest in and to the Inventions. 
 B. Pre-Existing Materials. Subject to Section 4.A, Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention or utilizes in the performance of
the Services any pre-existing invention, discovery, original works of authorship, development, improvements, trade secret, concept, or other proprietary information or intellectual property right owned by
Consultant (“Prior Inventions”), (i) Consultant will provide the Company with prior written notice and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual,
in-evocable, transferable, worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative
works of, display, perform, and otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. Consultant will not knowingly
incorporate any invention, improvement, development, concept, discovery, work of authorship or other proprietary information owned by any third party into any Invention without Company’s prior written permission. Company understands that
Consultant makes to warranties or representations of any kind regarding any services provided by Consultant, or any invention, improvement, development, concept, discovery, work of authorship or other proprietary information disclosed to Company
during the term hereof. 
 C. Moral Rights. Any assignment to the Company of Inventions includes all rights of
attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the
like (collectively, “Moral Rights”). To the extent that Moral Rights cannot be assigned under applicable law, Consultant hereby waives and agrees not to enforce any and all Moral Rights, including, without limitation, any
limitation on subsequent modification, to the extent permitted under applicable law. 
 D. Maintenance of Records. Consultant
agrees to keep and maintain adequate, current, accurate, and authentic written records of all Inventions made by Consultant (solely or jointly with others) during the term of this Agreement, and for a period of three (3) years thereafter. The
records will be in the form of notes, sketches, drawing s, electronic files, reports, or any other format that is customary in the industry and/or otherwise specified by the Company. Such records are and remain the sole properly of the Company at
all times and upon Company’s request, Consultant shall deliver (or cause to be delivered) the same. 
 E. Further
Assurances. Consultant agrees to provide the Company, or its designee, at the Company’s expense, with reasonable assistance in securing the Company’s rights in Inventions in any and all countries, including the disclosure to the
Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments that the Company may deem necessary in order to apply for, register, obtain,
maintain, defend, and enforce such rights, and in order to deliver, assign and convey to the Company, its successors, assigns and nominees the sole and exclusive right, title, and interest in and to all Inventions and testifying in a suit or other
proceeding relating to such Inventions. Consultant further agrees that Consultant’s obligations under this Section 4.E shall continue after the termination of this Agreement. 

  
 -3- 

 F.
Attorney-in-Fact. Consultant agrees that, if the Company is unable because of Consultant’s unavailability, dissolution, mental or physical incapacity,
or for any other reason, to secure Consultant’s signature with respect to any Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or foreign patents or mask work or
copyright registrations covering the Inventions assigned to the Company in Section 4.A, then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant’s agent and attorney-in-fact, to act for and on Consultant’s behalf to execute and file any papers and oaths and to do all other lawfully permitted acts with respect to such
Inventions to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by Consultant. This power of attorney shall be deemed coupled with an interest, and shall be
irrevocable. 
 5. Conflicting Obligations 

A. A Consultant represents and warrants that Consultant has no agreements, relationships, or commitments to any other person or entity that
conflict with the provisions of this Agreement, Consultant’s obligations to the Company under this Agreement, and/or Consultant’s ability to perform the Services. Consultant will not enter into any such conflicting agreement during the
term of this Agreement. 
 B. Consultant shall require all Consultant’s employees, contractors, or other third- parties performing
Services under this Agreement to execute a confidential information and assignment agreement in a form no less restrictive than this Agreement, and promptly provide a copy of each such executed agreement to the Company. Consultant’s violation
of this Article 5 will be considered a material breach under Section 8.B. 
 C. Consultant represents and warrants that Consultant,
and, to Consultant’s knowledge, its officers, directors, employees, and agents acting on its behalf, if applicable, have complied in all material respects with any and all applicable law, statute, order, decree, consent decree, judgment, rule,
regulation, ordinance or other pronouncement having the effect of law whether in the United States, any foreign country, or any domestic or foreign state, county, city or other political subdivision or of any governmental entity, and other
governmental requirements, including, but not limited to, federal, state, local and foreign laws, ordinances, rules, regulations and other requirements (collectively, “Laws”) to which Consultant may be subject to and which relate to
the subject matter of this Agreement, including Consultant’s provision of Services under this Agreement, and no claims have been filed against Consultant alleging a violation of any such Laws and Consultant has not received any notice asserting
that it is not so in compliance. 
 6. Return of Company Materials 

Upon the termination of this Agreement, or upon Company’s earlier request, Consultant will immediately deliver to the Company, and will
not keep in Consultant’s possession, recreate, or deliver to anyone else, any and all Company property, including, but not limited to, Confidential Information, tangible embodiments of the Inventions, all devices and equipment belonging to the
Company, all electronically-stored information and passwords to access such property, those records maintained pursuant to Section 4.D and any reproductions of any of the foregoing items that Consultant may have in Consultant’s possession
or control. 

  
 -4- 

 7. Reports 

Consultant agrees that Consultant will keep the Company advised as to Consultant’s progress in performing the Services under this
Agreement. Consultant further agrees that Consultant will, as reasonably requested by the Company, prepare written reports with respect to such progress. The Company and Consultant agree that the reasonable time expended in preparing such written
reports will be considered time devoted to the performance of the Services. 
 8. Term and Termination 

A. Term. The term of this Agreement will begin on the Effective Date of this Agreement and will continue until the earlier of
(i) final completion of the Services or (ii) termination as provided in Section 8.B. 
 B. Termination. Except
as otherwise provided in Exhibit A-l, either party may terminate this Agreement upon giving the other thirty (30) days prior written notice of such termination pursuant to Section 13.G of this
Agreement. Either Party may terminate this Agreement immediately and without prior notice if the other party is in breach of any material provision of this Agreement. 

C. Survival. Upon any termination, all rights and duties of the Company and Consultant toward each other shall cease except:

 (1) The Company will pay, within thirty (30) days after the effective date of termination, all undisputed amounts owing to
Consultant for Services completed prior to the termination date and related reimbursable expenses, if any, submitted in accordance with the Company’s policies and in accordance with the provisions of Article 1 of this Agreement; and 

(2) Article 3 (Confidentiality), Article 4 (Ownership), Section 5.B (Conflicting Obligations), Article 6 (Return of Company Materials),
Article 8 (Term and Termination), Article 9 (Independent Contractor Relationship), Article 10 (Indemnification), Article 11 (Noninterference), Article 12 (Limitation of Liability), and Article 13 (Miscellaneous) will survive termination or
expiration of this Agreement in accordance with their terms. 
 9. Independent Contractor Relationship 

It is the express intention of the Company and Consultant that Consultant perform the Services as an independent contractor to the Company.
Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent, employee or representative of the Company. Without limiting the generality of the foregoing, Consultant is not authorized to bind the Company to any
liability or obligation or to represent that Consultant has any such authority. Consultant agrees to furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement and shall incur all expenses associated with
performance, except as expressly provided in Exhibit A. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement. 

10. Indemnification 
 Each
Party agrees to indemnify and hold harmless the other party and the other party’s affiliates and their directors, officers and employees from and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys’
fees and other legal expenses, arising directly or indirectly from or in connection with (i) any negligent, reckless or intentionally wrongful act of the indemnifying party or the indemnifying party’s assistants, employees, contractors or
agents, and (ii) any breach by the indemnifying party or the indemnifying party’s assistants, employees, contractors or agents of any of the covenants contained in this Agreement. 

11. Nonsolicitation 
 To
the fullest extent permitted under applicable law, from the date of this Agreement until six (6) months after the termination of this Agreement for any reason (the “Restricted Period”), Consultant will not, without the
Company’s prior written consent, directly or indirectly, solicit any of the Company’s employees to leave their employment, or attempt to solicit employees of the Company, either for Consultant or for any other person or entity. Consultant
agrees that nothing in this Article 11 shall affect Consultant’s continuing obligations under this Agreement during and after this six (6) month period, including, without limitation, Consultant’s obligations under Article 3. 

  
 -5- 

 12. Limitation of Liability 

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO OTHER PARTY OR TO ANY OTHER THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL
DAMAGES, OR DAMAGES FOR LOST PROFITS OR LOSS OF BUSINESS, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, REGARDLESS OF WHETHER COMPANY WAS ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. IN NO EVENT SHALL COMPANY’S LIABILITY ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT EXCEED THE AMOUNTS PAID BY COMPANY TO CONSULTANT
UNDER THIS AGREEMENT FOR THE SERVICES, DELIVERABLES OR INVENTION GIVING RISE TO SUCH LIABILITY. IN NO EVENT SHALL CONSULTANT’S LIABILITY ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT EXCEED THE AMOUNTS RECEIVED BY CONSULTANT FROM THE
COMPANY UNDER THIS AGREEMENT FOR THE SERVICES, DELIVERABLES OR INVENTION GIVING RISE TO SUCH LIABILITY. 
 13. Miscellaneous 

A. Governing Law; Consent to Personal Jurisdiction. This Agreement shall be governed by the laws of the State of California,
without regard to the conflicts of law provisions of any jurisdiction. To the extent that any lawsuit is permitted under this Agreement, the Parties hereby expressly consent to the personal and exclusive jurisdiction and venue of the state and
federal courts located in California. 
 B. Assignability. This Agreement will be binding upon Consultant’s assigns,
administrators, and other legal representatives, and will be for the benefit of the Company, its successors, and its assigns. There are no intended third-party beneficiaries to this Agreement, except as expressly stated. Except as may otherwise be
provided in this Agreement, Consultant may not sell, assign or delegate any rights or obligations under this Agreement. Notwithstanding anything to the contrary herein, Company may assign this Agreement and its rights and obligations under this
Agreement to any successor to all or substantially all of Company’s relevant assets, whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock, or otherwise. 

  
 -6- 

 C. Entire Agreement. This Agreement constitutes the entire agreement and
understanding between the Parties with respect to the subject matter herein and supersedes all prior written and oral agreements, discussions, or representations between the Parties. Consultant represents and warrants that it is not relying on any
statement or representation not contained in this Agreement. To the extent any terms set forth in any exhibit or schedule conflict with the terms set forth in this Agreement, the terms of this Agreement shall control unless otherwise expressly
agreed by the Parties in such exhibit or schedule. 
 D. Headings. Headings are used in this Agreement for reference only and
shall not be considered when interpreting this Agreement. 
 E. Severability. If a court or other body of competent
jurisdiction finds, or the Parties mutually believe, any provision of this Agreement, or portion thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible so as to affect the intent of the Parties,
and the remainder of this Agreement will continue in full force and effect. 
 F. Modification, Waiver. No modification of or
amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in a writing signed by the Parties. Waiver by the Company of a breach of any provision of this Agreement will not operate as a waiver of any
other or subsequent breach. 
 G. Notices. Any notice or other communication required or permitted by this Agreement to be
given to a Party shall be in writing and shall be deemed given (i) if delivered personally or by commercial messenger or courier service, (ii) when sent by confirmed facsimile, or (iii) if mailed by U.S. registered or certified mail
(return receipt requested), to the Party at the Party’s address written below or at such other address as the Party may have previously specified by like notice. If by mail, delivery shall be deemed effective three business days after mailing
in accordance with this Section 14.G. 
  

	 	(1)	 If to the Company, to: 

 

	 	 	 2210 Faraday Avenue, Suite 100 

	 	 	 Carlsbad, CA 92008 

	 	 	 Attention: Vince Burges – President / CEO 

(2) If to Consultant, to the address for notice on the signature page to this Agreement or, if no such address is provided, to the last
address of Consultant provided by Consultant to the Company, with copy of each notice provided to Seyamack Kouretchian, Coast Law Group, LLP, [****] 

H. Attorneys’ Fees. In any court action at law or equity that is brought by one of the Parties to this Agreement to enforce
or interpret the provisions of this Agreement, the prevailing Party will be entitled to reasonable attorneys’ fees, in addition to any other relief to which that Party may be entitled. 

I. Signatures. Th.is Agreement may be signed in two counterparts, each of which shall be deemed au original, with the same force
and effectiveness as though executed in a single document. 
 (signature page follows) 

  
 -7- 

 IN WITNESS WHEREOF, the Parties hereto have executed this Consulting Agreement as of the
date first written above. 
  

									
	ELIAS HEALTH SCIENCES, INC.	 		 	ACUTUS MEDICAL, INC.
					
	By:	 	/s/ Peter Elia	 		 	By:	 	/s/ Gary Doherty
	Name:	 	Peter Elia	 		 	Name:	 	Gary Doherty
	Title:	 		 		 	Title:	 	CFO
	Date:	 	1/4/2019	 		 	Date:	 	1/4/2019

 Address for Notice: 

Acutus Medical, Inc. – Consulting Agreement 

 EXHIBIT A-1 

SERVICES AND COMPENSATION 

l. Contact. Consultant’s principal Company contact: 

Name: Vince Burgess 

Title: CEO 

Email: [****] 

Phone: [****] 

2. Services. The Services shall consist of the following: 

 

	 	•	 	 Market Development Consultant 

 

	 	•	 	 Peer-to-peer physician
engagement, including planning and execution 

  

	 	•	 	 Guidance, strategic planning, and implementation for site selection and pricing ! 

 

	 	•	 	 Establish national accounts and contracts 

 

	 	•	 	 Product features and performance requirements 

 

	 	•	 	 Other activities, as mutually agreed, including those typically required when introducing an advanced/new
technology to at medical specialty. 

  

	 	•	 	 The Company and the Consultant agree that, unless Company and Consultant mutually agree to earlier termination,
the Services shall be for a minimum of 3 months. If such notice is given before the minimum 3-month period ends, unless Consultant otherwise agrees, termination will not be effective until the end of the
minimum 3 month period. For the avoidance of doubt, the effect of this provision is to provide Consultant with a total of at least 3 months compensation for Services, unless Company and Consultant mutually agree to earlier termination or unless
there is a breach of a material term of the Agreement. 

  

	 	•	 	 Compensation. 

A. The Company will pay Consultant $31,250 per month at a fixed rate for the duration of the consultancy. 

B. The Company will reimburse Consultant, in accordance with Company policy, for all reasonable expenses incurred by Consultant in performing
the Services pursuant to this Agreement, if Consultant receives written consent from an authorized agent of the Company prior to incurring such expenses and submits receipts for such expenses to the Company in accordance with Company policy. 

 C. Subject to board approval, the Company will agree to grant 15,000 options to purchase
Common Stock at the then current fair market value (as established by the board based on an active 409a valuation) for each month of paid Service. In the event Service is terminated, Consultant will have 12 months to exercise any options granted.

 Monthly or every two weeks, Consultant shall submit to the Company a written invoice for Services and expenses. Company shall pay any
such undisputed invoices within 15 days of receipt. The Company shall promptly give Consultant notice of any unapproved invoices or disputed amounts 
  

									
	CONSULTANT	 		 	ACUTUS MEDICAL, INC.
					
	By:	 	/s/ Peter Elia	 		 	By:	 	/s/ Gary Doherty
	Name:	 	Peter Elia	 		 	Name:	 	Gary Doherty
	Title:	 		 		 	Title:	 	CFO
	Date:	 	1/4/19	 		 	Date:	 	1/4/2019

  
 -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]